Burst Biologics Spinal Fusion Study

Burst Biologics received Institutional Review Board approval for a U.S. prospective clinical study of BioBurst cellular allograft in spinal fusion patients. BioBurst Fluid, derived from umbilical cord blood, will be studied at 15 clinical sites enrolling 450 patients. Targeted follow-up is one year.

A multicenter patient registry was...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us